Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 4, 2025
Data Byte
Bispecifics overtake ADCs in China deals
Western biopharmas signed more deals for bispecifics than ADCs with China biotechs last year
BioCentury | Feb 27, 2025
Discovery & Translation
Science Spotlight: Clues from the clinic for neoantigen prioritization
BioCentury’s roundup of translational innovations also includes causal biology for a heart condition, and the biological foundational model Evo 2
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Feb 11, 2025
Data Byte
FDA’s new and supplemental approvals in January
Vertex’s Nav1.8 inhibitor, Axsome’s acute migraine therapy and Daiichi-AZ’s two ADCs for breast cancer among the month’s approvals
BioCentury | Feb 5, 2025
Product Development
Biotechs make inroads to precision medicine, solving long-standing problems
70% of new precision medicines approved by FDA in past three years were not sponsored by major pharmas
BioCentury | Jan 24, 2025
Finance
Ascentage lists on NASDAQ as Odyssey, Sionna, Aardvark plot IPOs
In BioCentury’s Finance Report, two more companies plan Hong Kong listings; Disc Medicine, Arctic raise cash
BioCentury | Jan 22, 2025
Product Development
Vir, Sana gain new modality POC: BioCentury’s Clinical Report
Plus readouts from Jasper, Dyne and more
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: Bispecifics poised to enter new era
Decade after first approval, bispecifics on the precipice of going mainstream
Items per page:
1 - 10 of 2741